logo
Plus   Neg
Share
Email

ImmunityBio Announces FDA Authorization To Begin Phase I Trial Of COVID-19 Vaccine Candidate

ImmunityBio, Inc. has received authorization from the FDA to begin a phase I clinical trial of hAd5-COVID-19, the company's COVID-19 vaccine candidate. The company plans launching a phase I trial in the current month with adult subjects up to age 55.

ImmunityBio, Inc. is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. In August, ImmunityBio, and its affiliate NantKwest, Inc. agreed to share equally the costs of development, manufacturing, marketing and commercialization of the products each is developing related to COVID-19, including the hAd5 vaccine candidate.

For comments and feedback contact: editorial@rttnews.com

Follow RTT